Toggle Main Menu Toggle Search

Open Access padlockePrints

Efficiency and Health Economic Evaluations of BD OneFlow™ Flow Cytometry Reagents for Diagnosing Chronic Lymphoid Leukemia

Lookup NU author(s): Eoin Moloney, Dr Joy AllenORCiD, Dr Peter Carey, Dr Louise Johnston, Rachel O'Leary, Dr Michael Power, Dr Jonathan Wallis, Professor John SimpsonORCiD, Dr Brigit Greystoke



This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).


© 2019 The Authors. Cytometry Part B: Clinical Cytometry published by Wiley Periodicals, Inc. on behalf of International Clinical Cytometry Society. Reason for the study: To standardize the use of flow cytometry for classifying hematological malignancies and make the results reliable and reproducible across laboratories, the EuroFlow™ Consortium published a comprehensive specification of antibody-fluorochrome conjugates, standard protocols, and algorithms for analysis. The BD OneFlow™ system builds on, and further standardizes, the EuroFlow protocols. We aimed to assess the effects on safety, efficiency, and costs for laboratories of adopting the BD OneFlow reagent tubes (LST and B-CLPD T1) for diagnosing chronic lymphocytic leukemia. Methods: We compared in-house laboratory processes and results with those using the LST and B-CLPD T1 reagent tubes with, and without, blood film morphology. Outcome measures included concordance in classification results, and efficiency within the laboratory, that is, resource usage, staff time, unwanted events, and cost-consequences. Results: There was 100% concordance between the classifications made with in-house flow cytometry and those with the BD OneFlow reagent tubes. Using BD OneFlow tubes required 13 hours less staff time per month (i.e. for 100 samples) than the in-house process. Sensitivity analyses explored the effects of uncertainties in the price of the BD OneFlow tubes and the prevalence of CLL and identified the thresholds at which laboratories might expect cost-savings from adopting the BD OneFlow system. Laboratory and clinical staff considered the BD OneFlow system to be safe and effective. Conclusions: Laboratories adopting the BD OneFlow system for classifying patients with suspected CLL can expect safe, efficient processes that can be cost saving if the discount on the list price, and prevalence of CLL (which will both vary between sites and countries), is within the thresholds suggested by the health economics sensitivity analysis. © 2019 International Clinical Cytometry Society.

Publication metadata

Author(s): Moloney E, Watson H, Barge D, Allen AJ, Carey P, Hislop J, Johnston L, Lorrison K, McGregor A, O'Leary RA, Power MH, Wallis J, Simpson AJ, Greystoke B

Publication type: Article

Publication status: Published

Journal: Cytometry Part B: Clinical Cytometry

Year: 2019

Volume: 96

Issue: 6

Pages: 514-520

Print publication date: 01/11/2019

Online publication date: 02/04/2019

Acceptance date: 08/02/2019

Date deposited: 25/04/2019

ISSN (print): 1552-4949

ISSN (electronic): 1552-4957

Publisher: John Wiley and Sons Inc.


DOI: 10.1002/cyto.b.21779


Altmetrics provided by Altmetric


Funder referenceFunder name
BD Biosciences
MIC-2016-014National Institute for Health Research (NIHR)